Acarbose vs Dasatinib + Quercetin (Senolytic Stack)

Mechanism

Acarbose is a complex oligosaccharide that competitively inhibits alpha-glucosidase enzymes (maltase, isomaltase, sucrase, glucoamylase) in the brush border of the small intestinal enterocytes, delaying the digestion and absorption of dietary carbohydrates. This blunts postprandial glucose and insulin spikes, reducing glycemic variability. In the longevity context, chronic postprandial glucose/insulin reduction mimics aspects of caloric restriction signaling, potentially reducing mTOR activation, AGE formation, and oxidative stress. Undigested carbohydrates reaching the colon serve as prebiotics, increasing short-chain fatty acid (SCFA) production by gut bacteria.

Standard Dosing

Research indicates 25-100 mg taken with the first bite of each carbohydrate-containing meal, up to 3 times daily.

Timing

Must be taken with the first bite of a carbohydrate-containing meal — timing is critical for mechanism of action. Ineffective if taken without carbohydrates or after the meal.

Cycle Duration

Ongoing for longevity applications. Long-term use is well-established in diabetes management.

Side Effects

• Flatulence and bloating (very common — from colonic fermentation of undigested carbohydrates)
• Diarrhea
• Abdominal pain and cramping
• Elevated liver transaminases (rare, reversible — typically at doses >100 mg TID)

Contraindications

• Inflammatory bowel disease (Crohn's, ulcerative colitis)
• Intestinal obstruction or predisposition to obstruction
• Chronic intestinal diseases with maldigestion/malabsorption
• Severe renal impairment (creatinine >2.0 mg/dL)
• Cirrhosis
• Known hypersensitivity to acarbose
• GI intolerance
• IBD or bowel obstruction

Best Stacking Partners

Mechanism

Dasatinib is a multi-kinase inhibitor (targeting SRC, ABL, c-KIT, PDGFR, and ephrin receptors) originally developed for chronic myeloid leukemia. Quercetin is a natural flavonoid that inhibits PI3K, serpine/PAI-2, BCL-xL, and other anti-apoptotic pathways. Together, they constitute a senolytic combination that selectively induces apoptosis in senescent cells by disabling the senescent cell anti-apoptotic pathways (SCAPs) that allow damaged, non-dividing cells to resist programmed cell death. Senescent cells accumulate with aging and secrete the SASP (senescence-associated secretory phenotype) — inflammatory cytokines, matrix metalloproteinases, and growth factors that drive tissue dysfunction. By clearing senescent cells, D+Q reduces SASP-driven chronic inflammation.

Standard Dosing

Research indicates Dasatinib 100 mg + Quercetin 1000-1250 mg orally for 2 consecutive days, repeated every 2-4 weeks (intermittent 'hit-and-run' dosing).

Timing

Take both compounds together on dosing days, with or without food. The 'hit-and-run' approach exploits the fact that senolytic effect occurs rapidly but senescent cells take weeks to re-accumulate. Quercetin bioavailability is improved by fat co-ingestion.

Cycle Duration

Ongoing intermittent cycles. Long-term safety data in healthy populations is limited. Typically used in periodic courses (e.g., 2 days per month for 3-6 months, then reassess).

Side Effects

• GI discomfort, nausea, diarrhea (both compounds)
• Fluid retention and peripheral edema (dasatinib)
• Headache
• Thrombocytopenia and neutropenia (dasatinib — typically mild at senolytic doses)
• Pleural effusion (rare at intermittent dosing; more common with chronic oncology dosing)
• Skin rash

Contraindications

• Active bleeding disorders or thrombocytopenia
• Severe hepatic impairment
• Pulmonary arterial hypertension
• QT prolongation risk or concurrent QT-prolonging drugs
• Pregnancy and breastfeeding
• Active infections (temporary immunosuppression)

Best Stacking Partners